Welcome to our dedicated page for Amgen SEC filings (Ticker: AMGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amgen Inc. (AMGN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed biotechnology issuer and a component of the Dow Jones Industrial Average and Nasdaq-100 Index, Amgen uses SEC filings to report financial results, material events and other information relevant to shareholders.
Amgen’s Form 8-K filings illustrate how the company communicates quarterly performance. For example, 8-K reports dated August 5, 2025 and November 4, 2025 describe second and third quarter earnings press releases, including unaudited results of operations and financial position. These filings also explain Amgen’s use of non-GAAP financial measures such as non-GAAP earnings per share, non-GAAP operating income, non-GAAP operating margin, non-GAAP tax rate, non-GAAP operating expenses and Free Cash Flow. The company outlines which acquisition-related expenses, restructuring charges and other items are excluded from GAAP results and how the related tax effects are calculated.
On this page, users can review Amgen’s current and historical SEC documents, including Forms 10-K and 10-Q when available, 8-Ks for earnings and other material events, and additional filings that may address debt offerings, governance matters or other disclosures. Stock Titan enhances these filings with AI-powered summaries that highlight key points, helping readers quickly understand topics such as segment performance, non-GAAP adjustments, liquidity metrics and risk factor discussions without reading every page.
The filings page also surfaces information relevant to questions about AMGN stock, such as how management describes its financial performance, what non-GAAP metrics it emphasizes and how it discusses acquisition-related charges and restructuring initiatives. Real-time updates from EDGAR, combined with AI-generated overviews, allow investors to follow new Amgen filings as they appear and to place each document in the context of the company’s broader financial and regulatory history.
Amgen Inc. is asking stockholders to vote at its May 19, 2026 virtual annual meeting on four items: electing 12 directors, an advisory “Say on Pay” vote, ratifying Ernst & Young as auditor for 2026, and a stockholder proposal for an independent board chair, which the Board recommends voting against.
The proxy highlights strong 2025 execution, including 10% year-over-year revenue and sales growth, record sales for 18 products, 14 products each exceeding $1 billion in sales, and five U.S. FDA approvals. Amgen reports 37% sales growth in its biosimilar portfolio to $3 billion and notes that more than 25% of revenue comes from non-U.S. markets.
The company is investing heavily in U.S. manufacturing, following a prior $1 billion North Carolina expansion with additional commitments of $900 million in Ohio and $650 million in Puerto Rico, aimed at boosting capacity, yields, and supply resilience. Executive pay is described as performance-based, with 80% of annual long-term equity awards tied to performance and a 2025 annual incentive plan payout at 136% of target based on financial and strategic results.
The Vanguard Group filed Amendment No. 11 on a Schedule 13G/A reporting 0 shares of Amgen Inc. common stock. The filing states that, following an internal realignment on 01/12/2026, certain Vanguard subsidiaries now report beneficial ownership separately pursuant to SEC Release No. 34-39538 (01/12/1998), and The Vanguard Group no longer is deemed to beneficially own securities held by those subsidiaries. The amendment lists Amount beneficially owned: 0 and Percent of class: 0%, with all voting and dispositive powers shown as 0.
Amgen Inc. executive Esteban Santos, EVP of Operations, reported an automatic share disposition tied to taxes rather than an open-market trade. On March 16, 2026, 5,621 shares of common stock were transferred at $366.21 per share to satisfy a tax liability by delivering securities.
After this transaction, Santos directly holds 82,404 common shares, which include 696 Dividend Equivalents that will pay out in shares as restricted stock units vest. He also has an additional indirect holding of 909.9928 shares through Amgen's 401(k) Plan stock fund.
AMGEN INC executive David M. Reese reported a compensation-related share disposition tied to tax obligations. On March 16, 2026, 6,022 shares of Amgen common stock were delivered at $366.21 per share to satisfy tax liability or exercise costs, a transaction coded as tax-withholding. Following this event, Reese directly held 41,787 Amgen shares. A portion of his position also reflects dividend equivalents credited to unvested restricted stock units that will be paid in shares as they vest.
Amgen Inc. senior vice president Derek Miller reported a routine tax-withholding transaction in company stock. On March 16, 2026, 1,616 shares of Amgen common stock were disposed of at $366.21 per share to satisfy tax obligations related to equity compensation. Following this withholding, Miller directly holds 12,173 shares, which include 197 dividend equivalents tied to unvested restricted stock units that will pay out in shares as they vest.
Amgen Inc. senior vice president of business development Rachna Khosla reported a tax-related share disposition on company stock. On March 16, 2026, 707 shares of Amgen common stock were withheld at a price of $366.21 per share to satisfy tax obligations, rather than sold in the open market.
After this tax-withholding disposition, Khosla directly holds 8,291 Amgen shares. This amount includes 120 Dividend Equivalents granted under Amgen’s 2009 equity incentive plan, which convert into common stock on a one-to-one basis as related restricted stock units vest.
Amgen Inc. senior vice president and chief compliance officer Nancy A. Grygiel reported a routine tax-related share withholding. On March 16, 2026, 787 shares of Amgen common stock were disposed of at $366.21 per share to satisfy tax obligations tied to equity compensation.
After this tax-withholding disposition, she directly holds 8,488 Amgen shares, which include 122 dividend equivalents that will pay out in shares as they vest. She also indirectly holds 106.1873 shares through the company’s 401(k) plan stock fund.
Amgen Inc. EVP & CFO Peter H. Griffith reported a Form 4 transaction showing a tax-related share disposition. On March 16, 2026, 5,748 shares of Amgen common stock were disposed of at $366.21 per share to satisfy tax obligations by delivering shares. After this withholding transaction, he directly holds 49,001 shares of common stock. His holdings include 756 Dividend Equivalents granted under Amgen’s equity incentive plan, which are paid out in shares on a one-for-one basis as related restricted stock units vest.
Amgen Inc. executive Jonathan P. Graham reported a routine tax-related share disposition. On this Form 4, 5,353 shares of Amgen common stock were withheld at $366.21 per share to satisfy tax obligations, rather than sold in the open market. After this withholding, he directly owns 39,267 shares. The reported holdings include 659 dividend equivalent units that will pay out in Amgen shares as related restricted stock units vest.